DoseMe Appoints Richard Malone, PharmD, MHA, as Vice President, Clinical & Science

DoseMe, a global leader in model-informed precision dosing (MIPD) software, today announced the appointment of Richard Malone, PharmD, MHA, as Vice President, Clinical & Science. In this role, Malone will lead the company’s clinical and scientific initiatives, including oversight of biostatistics, clinical content development, and alignment of scientific strategy with DoseMe’s broader growth objectives, including integration of newly acquired capabilities from Firstline.

ELRIG Announces Prof Hazel Screen and Dr Dave Powell as Keynote Speakers for Advances in Cell-based Screening 2026

• Free-to-attend conference takes place at AstraZeneca in Gothenburg, Sweden from 6–7 May • Programme to focus on advancement of animal-replacement technologies and transition towards human-first, AI-driven drug discovery

LabConnect Expands Global Central Laboratory Infrastructure with Wuxi, China Facility

LabConnect has officially opened a new central laboratory facility in Wuxi, China, developed in collaboration with Teddy Laboratory (Frontage Laboratories). The site integrates into LabConnect’s global infrastructure to provide unified data, custom kit building, and biorepository services for multi-regional clinical trials. This expansion brings the company to eight global locations, supporting both multinational firms entering China and Asia-Pacific organizations expanding their research internationally.

iXCells Biotechnologies reaches iPSC line delivery milestone in collaboration with global biotechnology company

Baylor Genetics Enhances Whole Genome Sequencing Test with Optical Genome Mapping and Long‑Read Sequencing as Supplemental Technologies

Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, today announced enhancements to its Whole Genome Sequencing (WGS) test with the addition of optical genome mapping (OGM) and long‑read sequencing (LRS) as supplemental technologies. These advanced technologies — along with RNA sequencing — enable the company’s WGS test to go beyond standard sequencing approaches, providing a more precise view of a patient’s genome and delivering more answers to help guide patient care and outcomes.

University of Colorado Grants License to Cirena for RNA-Synthesis Technology

Cirena has secured a license to the University of Colorado Boulder’s patented RNA synthesis technology.

Abselion Establishes US Subsidiary in Cambridge, MA

Supports closer engagement with scientists in North America, to meet growing international adoption of its Amperia protein quantification platform

Neuland to open commercial peptide facility as part of planned phased expansion

Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19

Cambridge Healthtech Institute today announced the agenda for the third annual Bio-IT World Venture, Innovation & Partnering Conference, an exclusive gathering of more than 200 senior-level investors, corporate executives, entrepreneurs and startups, with a focus on connecting capital, technology, and science to accelerate drug discovery.

More Than Half of GLP-1 Users Reported Seeking Follow-Up Care for Side Effects, Phenomix Sciences Report Finds

In conjunction with Obesity Care Week, a national survey from Phenomix Sciences among medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care. Real-world response varies: Many GLP-1 users reported variability in outcomes, including weight-loss plateaus, limited response, or weight gain. Care and costs often extend beyond the prescription: More than half of users required medical care to manage side effects, with some reporting significant out-of-pocket costs. One-size-fits-all falls short: The findings highlight that obesity treatment outcomes differ widely, reinforcing the need for more individualized approaches to care.

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.

Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies

Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies.

Ardena Appoints Paul Edwards as Chief People Officer

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening

• Drs Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg and Prof Tin Tin Su join SAB • Follows close of initial funding round with investment from Stephen Quake and Jay Flatley

Camgenium Expands NHS Access to Advanced, Risk-Adjusted Clinical Audit Analytics

Proscia Earns Top Performance Score in the US, Sweeping 2026 KLAS Digital Pathology Ratings

Following Proscia’s Global Best in KLAS win in Europe, Concentriq is now the highest-rated digital pathology platform across multiple regions

START Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business Unit

Dr. Smith will strengthen XenoSTART’s position as a premier drug development partner, translating PDX-driven insights into faster, more confident oncology development decisions.

Symbiosis Appoints Joanne Anderson as Chief Commercial Officer

Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment

ELRIG Appoints Dr Kelly Gray and Dr Elaine Duncan to its Board

• Strengthens leadership team to support next phase of growth as organisation evolves to meet needs of global drug discovery community • Drs Gray and Duncan to lead scientific programmes and early career initiatives, respectively